Regeneron Surges 3.24% on Groundbreaking Myeloma Drug Data – Is This the Catalyst for a New Bull Run?

Summary
• Regeneron (REGN) rockets to $715.05, up 3.24% intraday, hitting a 52-week high of $717.88.
• Preliminary trial data shows Lynozyfic eliminates residual multiple myeloma, bypassing bone marrow transplants.
• RBC Capital maintains a Hold rating at $708, while insider selling and sector volatility add complexity.

Regeneron’s stock is surging on a medical breakthrough with Lynozyfic, a dual-target antibody that eradicates residual myeloma cells in early trials. The stock’s 3.24% gain reflects optimism over reduced treatment burdens for patients and potential market expansion. With a 52-week high of $790.98 still in reach, investors are weighing the drug’s commercial potential against sector-wide challenges.

Lynozyfic’s Trial Success Sparks Optimism
Regeneron’s 3.24% intraday surge is directly tied to preliminary data from a mid-stage trial of Lynozyfic, its dual-target antibody for multiple myeloma. The drug, which binds to both CD3 (T cells) and BCMA (myeloma cells), eliminated residual disease in 18 of 18 patients, potentially replacing grueling bone marrow transplants. This breakthrough positions Lynozyfic as a first-line therapy, expanding Regeneron’s market share in a $5.5B myeloma treatment space. Analysts highlight the drug’s mechanism as a competitive edge over single-target therapies, though long-term efficacy and manufacturing risks remain unproven.

Biotech Sector Volatility Amid Mixed GLP-1 Drug Data
Options Playbook: Leveraging Lynozyfic’s Momentum
• MACD: 18.27 (bullish divergence from signal line 29.23)
• RSI: 41.89 (oversold territory, suggesting rebound potential)
• Bollinger Bands: Price at $715.05, 6.5% below upper band ($795.76), indicating consolidation before a breakout.
• 200D MA: $598.90 (far below current price, signaling long-term strength)

Top Options Contracts:
• REGN20251219C720 (Call, $720 strike, 12/19 expiry):
- IV: 27.57% (moderate volatility)
- Leverage Ratio: 64.43% (high gearing)
- Delta: 0.4589 (moderate sensitivity to price moves)
- Theta: -1.8035 (rapid time decay)
- Gamma: 0.01216 (responsive to price swings)
- Turnover: 4,005 (liquid)
- Payoff at 5% Upside ($750.80): $30.80 per contract. This call offers aggressive leverage for a 5% price move, ideal for short-term bets on Lynozyfic-driven momentum.

• REGN20251219C725 (Call, $725 strike, 12/19 expiry):
- IV: 23.51% (lower volatility)
- Leverage Ratio: 99.33% (extreme gearing)
- Delta: 0.3798 (moderate sensitivity)
- Theta: -1.4945 (slower decay)
- Gamma: 0.01368 (high responsiveness)
- Turnover: 7,309 (high liquidity)
- Payoff at 5% Upside ($750.80): $25.80 per contract. This contract balances leverage and time decay, suitable for a 3–5-day holding period if the stock breaks above $717.88.

Action: Aggressive bulls should target REGN20251219C720 into a confirmed breakout above $717.88. Conservative traders may use REGN20251219C725 as a core position, given its high gamma and liquidity.

Backtest Regeneron Stock Performance
The backtest of Regeneron (REGN) after a 3% intraday increase from 2022 to the present shows favorable performance metrics. The 3-day win rate is 51.72%, the 10-day win rate is 54.77%, and the 30-day win rate is 57.40%, indicating a higher probability of positive returns in the short term. The maximum return during the backtest was 1.88%, which occurred on day 54, suggesting that REGN can deliver modest gains following a 3% intraday surge.

Position for a Breakout – Lynozyfic Could Redefine Myeloma Care
Regeneron’s 3.24% surge is a pivotal moment for the stock, driven by Lynozyfic’s trial success and a dynamic technical setup. The 52-week high of $790.98 remains a distant target, but the 12/19 options chain offers near-term leverage. Watch for a breakout above $717.88 (intraday high) to confirm momentum. Meanwhile, sector leader Amgen (AMGN) is up 0.65%, signaling biotech resilience. Investors should prioritize REGN20251219C720 for a 5% upside scenario or REGN20251219C725 for a longer-term play. Act now: Position for a potential $750.80 target by December 19.